# GlaxoSmithKline and Sanofi delay COVID-19 vaccine programme

- Link: https://www.directorstalkinterviews.com/glaxosmithkline-and-sanofi-delay-covid-19-vaccine-programme/412947142
- Published: 2020-12-11T07:13:22+00:00
- Author: Amilia Stone

**[GlaxoSmithKline](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)
plc** ([LON:GSK](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l))
and Sanofi have announced a delay in their adjuvanted recombinant protein-based 
COVID-19 vaccine programme to improve immune response in the elderly.

·   Phase 1/2 interim results showed an immune response comparable to patients who
recovered from COVID-19 in adults aged 18 to 49 years

·   Insufficient response in older adults demonstrates the need to refine the concentration
of antigen in order to provide high-level immune response across all age groups

·   Companies plan a Phase 2b study with an improved antigen formulation

·   With support from BARDA as part of Operation Warp Speed, study to start in February
2021, including a proposed comparison with an authorised COVID-19 vaccine

·   Product availability now expected in Q4 2021 pending successful completion of
the development plan

Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-
19 vaccine program to improve immune response in older adults. Phase 1/2 study interim
results showed an immune response comparable to patients who recovered from COVID-
19 in adults aged 18 to 49 years, but a low immune response in older adults likely
due to an insufficient concentration of the antigen.

A recent challenge study in non-human primates performed with an improved antigen
formulation demonstrated that the vaccine candidate could protect against lung pathology
and lead to rapid viral clearance from the nasal passages and lungs, within 2 to
4 days. These results increase the Companies confidence in the capacity of the adjuvanted
recombinant platform to deliver a highly efficient vaccine for all adults.

Sanofi’s recombinant technology and GSK’s pandemic adjuvant are established vaccine
platforms that have proven successful against influenza. The recombinant technology
offers the advantages of stability at temperatures used for routine vaccines, the
ability to generate high and sustained immune responses, and the potential to prevent
virus transmission.

> “We care greatly about public health which is why we are disappointed by the delay
> announced today, but all our decisions are and will always be driven by science
> and data. We have identified the path forward and remain confident and committed
> to bringing a safe and efficacious COVID-19 vaccine. Following these results and
> the latest encouraging new preclinical data, we will now work to further optimise
> our candidate to achieve this goal,” **said Thomas Triomphe, Executive Vice President
> and Head of Sanofi Pasteur. **“No single pharma company can make it alone; the
> world needs more than one vaccine to fight the pandemic.”

> **Roger Connor, President of GSK Vaccines added: **“The results of the study are
> not as we hoped. Based on previous experience and other collaborations, we are
> confident that GSK’s pandemic adjuvant system, when coupled with a COVID-19 antigen,
> can elicit a robust immune response with an acceptable reactogenicity profile.
> It is also clear that multiple vaccines will be needed to contain the pandemic.
> Our aim now is to work closely with our partner Sanofi to develop this vaccine,
> with an improved antigen formulation, for it to make a meaningful contribution
> to preventing COVID-19.”

The Companies plan a Phase 2b study expected to start in February 2021 with support
from the Biomedical Advanced Research and Development Authority (BARDA), part of
the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) under
contract W15QKN-16-9-1002. The study will include a proposed comparison with an 
authorised COVID-19 vaccine. If data are positive, a global Phase 3 study could 
start in Q2 2021. Positive results from this study would lead to regulatory submissions
in the second half of 2021, delaying the vaccine’s potential availability from mid-
2021 to Q4 2021.

Sanofi and GSK adjuvanted recombinant-protein based vaccine candidate was selected
in July 2020 by U.S. government’s Operation Warp Speed in order to accelerate its
development and manufacturing.

The Companies have updated Governments and the European Commission where a contractual
commitment to purchase the vaccine has been made.

**Phase 1/2 study**

The interim Phase 1/2 results showed a level of neutralizing antibody titers after
two doses comparable to sera from patients who recovered from COVID-19, a balanced
cellular response in adults aged 18 to 49 years, but insufficient neutralising antibody
titers in adults over the age of 50. The candidate showed transient but higher than
expected levels of reactogenicity likely due to the suboptimal antigen formulation,
with no serious adverse events related to the vaccine candidate. The most favourable
results were observed in the group which tested the highest antigen concentration,
combined with the GSK adjuvant, showing neutralisation titers in 88% of participants.
Seroconversion was observed in 89.6% of the 18 to 49 age group; 85% in the >50 age
group; and 62.5% in the >60 age group.

The Phase 1/2 clinical study is a randomised, double blind and placebo-controlled
study designed to evaluate the safety, reactogenicity and immunogenicity (immune
response) of the COVID-19 vaccine candidate. A total of 440 healthy adults participated
in the study, across 10 investigational sites in the United States. The participants
received one or two doses of the vaccine candidate, or placebo at 21 days apart.

Full results of the Phase 1/2 study will be published as soon as all data are available,
following peer-reviewed publication process.

**Latest preclinical results**

A recent preclinical study using a highly virulent challenge in non-human primates,
showed high ability for the vaccine to protect against lung pathology and reduce
virus in the nose and lungs within 2-4 days. Results from this pre-clinical study
confirm strong ability of the vaccine candidate to stop the replication of the virus
with an optimal antigen formulation.

These data are being prepared for submission to a peer-reviewed publication.

**GSK commitment to tackling COVID-19**

GSK’s response to COVID-19 has been one of the broadest in the industry, with two
potential treatments in addition to our vaccine candidates in development.

GSK is collaborating with several organisations working on promising COVID-19 vaccines
by providing access to our adjuvant technology. In addition to work with Sanofi,
collaborations with Medicago and Clover Biopharmaceuticals on adjuvanted, protein-
based vaccine candidates are progressing into late-stage clinical trials. The use
of an adjuvant is of particular importance in a pandemic situation since it may 
reduce the amount of vaccine protein required per dose, allowing more vaccine doses
to be produced and therefore contributing to protecting more people. GSK does not
expect to profit from COVID-19 vaccines during the pandemic phase, and will invest
any short-term profit in coronavirus related research and long-term pandemic preparedness,
either through GSK internal investments or with external partners.

GlaxoSmithKline is also exploring potential therapeutic or treatment options for
COVID-19 patients. We are collaborating with Vir Biotechnology to develop existing
and identify new anti-viral antibodies that could be used as therapeutic or preventive
options for COVID-19. We are also assessing whether one of our potential new medicines,
otilimab -a monoclonal antibody – can help some COVID-19 patients who experience
an overreaction of their immune system, which can lead to hospitalisation or death.

Share on:
